Protein-Protein Interaction Inhibitors of BRCA1 Discovered Using Small Molecule Microarrays.

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Microarray screening is a powerful tool in life sciences for mapping interaction networks and discovering molecular inhibitors.
• Protein-protein interaction (PPI) inhibitors are crucial for understanding and targeting cellular processes.
• Mutations in the human BRCA1 gene are linked to approximately 50% of hereditary breast cancers.

Purpose of the Study:

• To demonstrate the application of microarray-guided screening for identifying small molecular inhibitors of protein-protein interactions.
• To discover novel inhibitors targeting the human BRCA1 protein, specifically its (BRCT)2 domain.
• To evaluate the potential of these inhibitors in cancer therapy.

Main Methods:

• Utilized microarray screening technology for high-throughput identification of PPI inhibitors.
• Focused on the human BRCA1 protein and its (BRCT)2 domain as a therapeutic target.
• Synthesized and tested small molecules, including compound 15a and its prodrug 15b, for their inhibitory activity.

Main Results:

• Successfully identified small molecules, compound 15a and prodrug 15b, that inhibit BRCA1 activities within tumor cells.
• Demonstrated that these compounds target the (BRCT)2 domain of human BRCA1.
• Showcased the direct administrability of these compounds to tumor cells, distinguishing them from peptide-based inhibitors.

Conclusions:

• Microarray-guided screening is effective for discovering direct-acting PPI inhibitors.
• Compound 15a and its prodrug 15b represent a new class of BRCA1 inhibitors with therapeutic potential.
• These inhibitors offer a promising strategy for targeting BRCA1/PARP-related pathways in cancer treatment, particularly in DNA damage and repair response.